Clinical data from IIT using Medigene's dendritic cell (DC) vaccines in prostate cancer presented at AACR conference
(Thomson Reuters ONE) -
Medigene AG /
Clinical data from IIT using Medigene's dendritic cell (DC) vaccines in prostate
cancer presented at AACR conference
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 19 April 2016. Medigene AG (MDG1, Frankfurt, Prime
Standard), a clinical stage immune-oncology company focusing on the development
of T cell immuno-therapies for the treatment of cancer, announces that clinical
data of a dendritic cell (DC) vaccine trial for the treatment of prostate cancer
were presented at the American Association for Cancer Research (AACR) Annual
Meeting in New Orleans, LA, USA.
The clinical data were collected, utilising Medigene's DC vaccine technology in
part, in an ongoing clinical phase I/II study on dendritic cell (DC) vaccines
for the treatment of prostate cancer at the Department of Cellular Therapy at
the Oslo University Hospital, Norway, under the responsibility of Prof. Gunnar
Kvalheim. The poster presented was entitled "Clinical results of a Phase I/II
trial of adjuvant therapeutic vaccination in high risk resected prostate cancer
patients using autologous dendritic cells loaded with mRNA from primary prostate
cancer tissue, hTERT and survivin".
More than 50% of high risk prostate cancer patients will develop an early
biochemical relapse, with no curative therapy presently available. Therefore,
Prof. Gunnar Kvalheim and his team have chosen this patient population for their
ongoing Phase I/II dendritic cell (DC) vaccine study. Dendritic cells from each
of the 20 enrolled patients were differentiated from enriched monocytes and
matured with one of two different maturation cocktails. The DCs were then
transfected with mRNA from primary prostate cancer tissue, hTERT and Survivin
and then frozen and stored until use. Based on encouraging clinical results with
a new type of DCs in patients with different types of tumours treated in a
compassionate use[1] programme, the DC vaccine protocol was changed to the use
of new generation DCs. The last five of 20 treated patients received DCs that
were matured with a new TLR7/8-agonist maturation cocktail developed by
Medigene. Three of 15 patients given DC vaccines derived with the old (standard)
maturation cocktail have experienced a biochemical relapse (raised levels of
prostate-specific antigen, PSA) during the vaccination period of 3 years. None
of the patients given the new type of DC vaccines has so far experienced a rise
in PSA levels.
Prof. Gunnar Kvalheim, Head of Department of Cellular Therapy, Oslo University
Hospital concluded on the results: "To our knowledge this is the first adjuvant
DC vaccine study in high risk prostate cancer and we conclude that the study is
feasible, safe and utmost promising."
Prof. Dolores J. Schendel, CEO/CSO of Medigene AG added: "We feel very
encouraged by these preliminary data. The advanced method of making DC vaccines
is identical with the method Medigene is also using in its own ongoing DC
vaccine study in acute myeloid leukaemia."
More detailed information on the presented data can be found under the following
link:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=ac456e79-
efd5-416e-a7de-67382c67723a&cKey=2ab5cd11-b3d8-40a8-8087-
b0c57f2e8034&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
The Oslo University Hospital has an agreement with Medigene for use of
Medigene`s new generation DC vaccines for their ongoing academic clinical
studies.
About Medigene's DC vaccines: The platform for the development of antigen-
tailored DC vaccines is the most advanced platform of the highly innovative and
complementary immunotherapy platforms of Medigene Immunotherapies. Currently,
Medigene evaluates its DC vaccines in a company-sponsored phase I/II clinical
trial in acute myeloid leukaemia (AML). Further studies utilising Medigene's DC
vaccine technology include two ongoing clinical investigator-initiated trials
(IITs): a clinical phase I/II trial for treating acute myeloid leukaemia (AML)
at Ludwig Maximilians University Hospital Grosshadern, Munich, and a clinical
phase II trial of a treatment for prostate cancer at Oslo University Hospital.
Moreover, compassionate use patients are treated with DC vaccines at the
Department of Cellular Therapy at Oslo University Hospital.
Dendritic cells (DCs) are the most potent antigen presenting cells of our immune
system. Their task is to take up, process and present antigens on their cell
surface, which enables them to activate antigen-specific T cells for maturation
and proliferation. This way T cells can recognise and eliminate antigen-bearing
tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to
attack tumour cells. The team of Medigene Immunotherapies GmbH's scientists has
developed new, fast and efficient methods for generating dendritic cells ex-
vivo, which have relevant characteristics to activate both T cells and NK cells.
The DC vaccines are developed from autologous (patient-derived) precursor cells,
isolated from the patient's blood, and can be loaded with tumour-specific
antigens to treat different types of cancer. Medigene's DC vaccines are in
development for the treatment of minimal residual disease or use in combination
therapies.
Further audio-visual education about Medigene's DC-Vaccines at:
https://vimeo.com/123005832
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. The company is
developing highly innovative, complementary treatment platforms to target
various types and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized T cell-
based immunotherapies.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademark of Medigene AG. This trademark may be
owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor(at)medigene.com). We will then delete your address
from our distribution list.
--------------------------------------------------------------------------------
[1] Compassionate Use: Prescription of as-yet unapproved drugs in particularly
severe cases where there are no treatment alternatives
Press release English PDF:
http://hugin.info/132073/R/2004464/740106.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#2004464]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Brazil Resources announces NI 43-101 gold resource for the Island Mountain deposit within the Whistler Project, AlaskaDatum: 19.04.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 464739
Anzahl Zeichen: 8173
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 328 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clinical data from IIT using Medigene's dendritic cell (DC) vaccines in prostate cancer presented at AACR conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
